

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 11

Complete if Known

Application Number 09/724,288
Filing Date November 27, 2000
First Named Inventor Dale B. Schenk
Group Art Unit 1647
Examiner Name Unassigned
Attorney Docket Number 15270J-004765US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	196	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	2	5,958,883		Snow	09-28-1999	
	3	5,955,317		Suzuki et al.	09-21-1999	
	4	5,955,079		Mond et al.	09-21-1999	
	5	5,877,399		Hsiao et al.	03-02-1999	
	6	5,869,093		Weiner et al.	02-09-1999	
	7	5,869,054		Weiner et al.	02-09-1999	
	8	5,854,204		Findeis et al.	12-29-1998	
	9	5,851,996		Kline	12-22-1998	
	10	5,849,298		Weiner et al.	12-15-1998	
	11	5,837,473		Maggio e al.	11-17-1998	
	12	5,786,180		Konig et al.	07-28-1998	
	207	5,780,587		Potter	07-14-1998	
	13	5,753,624		McMichael et al.	05-19-1998	
	14	5,750,349		Suzuki et al.	05-12-1998	
	197	5,744,368		Goldgaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	15	5,733,547		Weiner et al.	03-31-1998	
	16	5,688,651		Solomon	11-18-1997	
	17	5,679,348		Nesburn et al.	10-21-1997	
	18	5,645,820		Hafler et al.	07-08-1997	
	19	5,641,474		Hafler et al.	06-24-1997	
	20	5,641,473		Hafler et al.	06-24-1997	
	21	5,612,486		McConlogue et al.	03-18-1997	
	22	5,605,811		Seubert et al.	02-25-1997	
	23	5,585,100		Mond et al.	12-17-1996	
	24	5,571,500		Hafler et al.	11-05-1996	
	25	5,571,499		Hafler et al.	11-05-1996	
	175	5,441,870		Seubert, et al.	08-15-1995	
	26	5,434,170		Andrulis, Jr.	07-18-1995	
	27	5,387,742		Cordell	02-07-1995	
	181	5,270,165		Van Nostrand et al.	12-14-1993	
	28	5,231,000		Majocha et al.	07-27-1993	
	29	5,220,013		Ponte et al.	06-15-1993	

Examiner
Signature

[Signature]

Date
Considered

12-2-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3169611 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A PTO SEP 10 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 11

Complete if Known

Application Number 09/724,288
Filing Date November 27, 2000
First Named Inventor Dale B. Schenk
Group Art Unit 1647
Examiner Name Unassigned
Attorney Docket Number 15270J-004765US

30	5,208,036	Eppstein et al.	05-04-1993
31	5,192,753	McGeer et al.	03-09-1993
32	5,187,153	Cordell et al.	02-16-93
33	5,057,540	Kensil et al.	10-15-1991
198	5,004,697	Pardridge	04-0201991
34	4,666,829	Glenner et al.	05-19-1987

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	35	EP	911 036	A2		04-28-1999		<input type="checkbox"/>
	36	EP	868 918	A2		10-07-1998		<input type="checkbox"/>
	37	EP	863 211	A1		09-09-1998		<input type="checkbox"/>
	38	EP	845 270	A1		06-03-1998		<input type="checkbox"/>
	39	EP	782 859	A1		07-09-1997		<input type="checkbox"/>
	40	EP	683 234	A1		11-22-1995		<input type="checkbox"/>
	41	EP	666 080	A1		08-09-1995		<input type="checkbox"/>
	42	EP	652 962	B1		12-16-1998		<input type="checkbox"/>
	43	EP	639 081	B1		11-03-1999		<input type="checkbox"/>
	44	EP	613 007	A2		08-31-1994		<input type="checkbox"/>
	45	EP	594 607	B1		08-27-1997		<input type="checkbox"/>
	46	EP	561 087	B1		08-04-1999		<input type="checkbox"/>
	47	EP	526 511	B1		05-28-1997		<input type="checkbox"/>
	48	EP	506 785	B1		03-15-2000		<input type="checkbox"/>
	49	EP	451 700	A1		10-16-1991		<input type="checkbox"/>
	50	EP	440 619	B1		01-24-1996		<input type="checkbox"/>
	51	EP	359 783	B1		11-29-1995		<input type="checkbox"/>
	52	EP	276 723	B1		12-08-1993		<input checked="" type="checkbox"/>
	187	EP	783 104	A1		07-09-1997		<input type="checkbox"/>
	199	PCT	00/77178	A1		12-21-2000		<input type="checkbox"/>
	188	PCT	00/43049	A1		07-27-2000		<input type="checkbox"/>
	53	PCT	99/60024	A1		11-25-1999		<input type="checkbox"/>
	54	PCT	99/60021	A2		11-15-1999		<input type="checkbox"/>
	55	PCT	99/58564	A1		11-18-1999		<input type="checkbox"/>
	56	PCT	99/06066	A2		02-11-1999		<input type="checkbox"/>
	57	PCT	99/27949	A1		06-10-1999		<input type="checkbox"/>
	58	PCT	99/27944	A1		06-10-1999		<input type="checkbox"/>

Examiner Signature

Schenk

Date

Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 11

Complete if Known

Application Number 09/724,288
Filing Date November 27, 2000
First Named Inventor Dale B. Schenk
Group Art Unit 1647
Examiner Name Unassigned
Attorney Docket Number 15270J-004765US

59	PCT	99/27911	A1	06-10-1999	<input type="checkbox"/>
203	PCT	99/00150	A2	01-07-1999	<input type="checkbox"/>
60	PCT	98/44955	A1	10-15-1998	<input type="checkbox"/>
61	PCT	98/07850	A2	02-26-1998	<input type="checkbox"/>
202	PCT	97/21728	A1	06-19-1997	<input type="checkbox"/>
62	PCT	97/17613	A1	05-15-1997	<input type="checkbox"/>
63	PCT	96/39176	A1	12-12-1996	<input type="checkbox"/>
208	PCT	96/28471	A1	09-19-1996	<input type="checkbox"/>
64	PCT	96/25435	A1	08-22-1996	<input type="checkbox"/>
65	PCT	96/18900	A1	06-20-1996	<input type="checkbox"/>
66	PCT	95/31996	A1	11-30-1995	<input type="checkbox"/>
200	PCT	95/12815	A1	05-11-1995	<input type="checkbox"/>
67	PCT	95/11994	A1	05-04-1995	<input type="checkbox"/>
68	PCT	95/11311	A1	04-27-1995	<input type="checkbox"/>
69	PCT	95/05853	A1	03-02-1995	<input type="checkbox"/>
70	PCT	95/04151	A2	02-09-1995	<input type="checkbox"/>
201	PCT	94/28412	A1	12-08-1994	<input type="checkbox"/>
71	PCT	94/03615	A1	02-17-1994	<input type="checkbox"/>
72	PCT	94/01772	A1	01-20-1994	<input type="checkbox"/>
73	PCT	93/21950	A1	11-11-1993	<input type="checkbox"/>
74	PCT	93/16724	A1	09-02-1993	<input type="checkbox"/>
75	PCT	93/15760	A1	08-19-1993	<input type="checkbox"/>
76	PCT	93/14200	A1	07-22-1993	<input type="checkbox"/>
205	PCT	93/04194	A1	03-04-1993	<input type="checkbox"/>
77	PCT	93/02189	A1	02-04-1993	<input type="checkbox"/>
78	PCT	92/13069	A1	08-06-1992	<input type="checkbox"/>
79	PCT	92/06708	A1	04-30-1992	<input type="checkbox"/>
80	PCT	92/06187	A1	04-16-1992	<input type="checkbox"/>
81	PCT	91/19810	A1	12-26-1991	<input type="checkbox"/>
82	PCT	91/16819	A1	11-14-1991	<input type="checkbox"/>
83	PCT	91/12816	A1	09-05-1991	<input type="checkbox"/>
84	PCT	91/08760	A1	06-27-1991	<input type="checkbox"/>
85	PCT	90/12871	A1	11-01-1990	<input type="checkbox"/>
86	PCT	90/12870	A1	11-01-1990	<input type="checkbox"/>
87	PCT	89/01343	A1	02-23-1989	<input type="checkbox"/>
88	PCT	89/06242	A1	07-13-1989	<input type="checkbox"/>
89	PCT	89/06689	A1	07-27-1989	<input type="checkbox"/>
90	PCT	89/03687	A1	05-05-1989	<input type="checkbox"/>
91	PCT	88/10120	A1	12-29-1988	<input type="checkbox"/>

Examiner
Signature

[Signature]

Date
Considered

12-2-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3169611 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

SEP 10 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 11

Complete if Known

Application Number	09/724,288
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	15270J-004765US

92	GB	2 220 211	A	01-04-1990	<input type="checkbox"/>
93	GB	2 335 192	A	09-15-1999	<input type="checkbox"/>

Examiner
Signature

[Signature]

Date
Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1

Please type a plus sign (+) inside this box +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 11

Complete if Known

Application Number	09/724,288
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	15270J-004765US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<u>JS</u>	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," <u>Neurology</u> , 45:1441-1445 (1995).	<input type="checkbox"/>
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95).	<input type="checkbox"/>
	96	BAUER et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).	<input type="checkbox"/>
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> 29:345-354 (1999).	<input type="checkbox"/>
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> 18:764 (1992).	<input type="checkbox"/>
	176	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).	<input type="checkbox"/>
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999).	<input type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).	<input type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).	<input type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genet. Develop.</u> , 3: 102-109 (1993).	<input type="checkbox"/>
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).	<input type="checkbox"/>
	102	CHAO et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513.7 (1993).	<input type="checkbox"/>
	213	CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> 125:223-226 (1991).	<input type="checkbox"/>
	214	DEMATOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA</u> , 10.1073/pnas.151261398 (2001).	<input type="checkbox"/>
<u>JS</u>	103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995).	<input type="checkbox"/>

Examiner Signature

JS

Date Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6

of 11

Complete if Known

Application Number	09/724,288
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	15270J-004765US

104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).	<input type="checkbox"/>
105	FELSENSTEIN et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).	<input type="checkbox"/>
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).	<input type="checkbox"/>
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).	<input type="checkbox"/>
108	FLANDERS et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).	<input type="checkbox"/>
210	FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).	<input type="checkbox"/>
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).	<input type="checkbox"/>
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β ₁₋₄₂ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).	<input type="checkbox"/>
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).	<input type="checkbox"/>
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).	<input type="checkbox"/>
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998).	<input type="checkbox"/>
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).	<input type="checkbox"/>
114	GLENNER et al., "Alzheimer's Disease and Down's Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).	<input type="checkbox"/>
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).	<input type="checkbox"/>
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS</u> , 93:427-432 (1996).	<input type="checkbox"/>
190	GRAVINA et al., "Amyloid β Protein (A β) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).	<input type="checkbox"/>
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).	<input type="checkbox"/>
118	HAGA et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).	<input type="checkbox"/>

Examiner
Signature

[Signature]

Date

Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 11

Complete if Known

Application Number	09/724,288
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	15270J-004765US

119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	<input type="checkbox"/>
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	<input type="checkbox"/>
121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).	<input type="checkbox"/>
193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).	<input type="checkbox"/>
177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	<input type="checkbox"/>
122	HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	<input type="checkbox"/>
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	<input type="checkbox"/>
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	<input type="checkbox"/>
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	<input type="checkbox"/>
192	IWATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <u>Neuron</u> , 13:45-53 (1994).	<input type="checkbox"/>
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	<input type="checkbox"/>
216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> 138:373-378 (1991).	<input type="checkbox"/>
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).	<input type="checkbox"/>
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	<input type="checkbox"/>
128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).	<input type="checkbox"/>
195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the β A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).	<input type="checkbox"/>
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).	<input type="checkbox"/>
130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).	<input type="checkbox"/>

Examiner
Signature

[Signature]

Date
Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 11

Complete If Known

Application Number 09/724,288
Filing Date November 27, 2000
First Named Inventor Dale B. Schenk
Group Art Unit 1647
Examiner Name Unassigned
Attorney Docket Number 15270J-004765US

131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).	<input type="checkbox"/>
132	LEMERE et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part 1, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).	<input type="checkbox"/>
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).	<input type="checkbox"/>
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).	<input type="checkbox"/>
218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> , 33:2184-2189 (1992).	<input type="checkbox"/>
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	<input type="checkbox"/>
135	MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).	<input type="checkbox"/>
136	MEDA et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <u>Nature</u> , 374:647-650 (1995).	<input type="checkbox"/>
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).	<input type="checkbox"/>
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).	<input type="checkbox"/>
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).	<input type="checkbox"/>
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).	<input type="checkbox"/>
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	<input type="checkbox"/>
140	PARESCCE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).	<input type="checkbox"/>
141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).	<input type="checkbox"/>
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).	<input type="checkbox"/>
143	QUON et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).	<input type="checkbox"/>
144	RASO, V.A., Grant application #1-R43-AG1-5746-01, (publication date unknown) <i>Improper format</i>	<input type="checkbox"/>

Examiner
Signature

[Signature]

Date

Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3169611 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 11

Complete if Known

Application Number	09/724,288
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	15270J-004765US

145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	<input type="checkbox"/>
146	ROGERS et al., "Complement activation by β -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	<input type="checkbox"/>
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	<input type="checkbox"/>
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	<input type="checkbox"/>
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	<input type="checkbox"/>
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	<input type="checkbox"/>
178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	<input type="checkbox"/>
148	SCHENK et al., "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	<input type="checkbox"/>
149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	<input type="checkbox"/>
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	<input type="checkbox"/>
151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	<input type="checkbox"/>
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	<input type="checkbox"/>
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	<input type="checkbox"/>
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	<input type="checkbox"/>
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	<input type="checkbox"/>
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	<input type="checkbox"/>
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	<input type="checkbox"/>
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	<input type="checkbox"/>

Examiner
Signature

Date
Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/724,288
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	15270J-004765US

Sheet 10 of 11

159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <u>PNAS</u> , 94:4109-4112 (1997).	<input type="checkbox"/>
160	SOLOMON et al., "Monoclonal antibodies inhibit <i>in vitro</i> fibrillar aggregation of the Alzheimer β -amyloid peptide," <u>PNAS</u> , 93:452-455 (1996).	<input type="checkbox"/>
161	SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown). <i>improper format</i>	<input type="checkbox"/>
162	SOLOMON, B., "New Approach Towards Fast Induction of Anti- β -Amyloid-Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, Ramat-Aviv, Israel (publication date unknown). <i>improper format</i>	<input type="checkbox"/>
182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	<input type="checkbox"/>
184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).	<input type="checkbox"/>
185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	<input type="checkbox"/>
186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of <i>in vitro</i> aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown). <i>improper format</i>	<input type="checkbox"/>
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).	<input type="checkbox"/>
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria," <u>N. Engl. J. Med.</u> , 336(2): 86-91 (1997).	<input type="checkbox"/>
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).	<input type="checkbox"/>
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).	<input type="checkbox"/>
166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).	<input type="checkbox"/>
167	VAN GOOL et al., "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).	<input type="checkbox"/>
168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).	<input type="checkbox"/>
169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).	<input type="checkbox"/>
180	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).	<input type="checkbox"/>
170	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).	<input type="checkbox"/>

Examiner Signature

Schenk

Date Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 11

Complete if Known

Application Number	09/724,288
Filing Date	November 27, 2000
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	Unassigned
Attorney Docket Number	15270J-004765US

86	171	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	<input type="checkbox"/>
	172	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-874 (2000).	<input type="checkbox"/>
	219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8729-8732 (1985).	<input type="checkbox"/>
85	173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94: 1550-1555 (1997).	<input type="checkbox"/>
	174	Human Immunology & Cancer Program brochure from The University of Tennessee Medical Center/Graduate School of Medicine, Knoxville, Tennessee (publication date unknown). <i>Improperly formed</i>	<input type="checkbox"/>

Examiner
Signature

[Signature]

Date
Considered

12-2-02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3169611 v1